(MedPage Today) — DENVER — Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) had a trend toward better survival and longer time to treatment failure, according to long-term follow…
Source link : https://www.medpagetoday.com/meetingcoverage/ikcs/118606
Author :
Publish date : 2025-11-19 20:31:00
Copyright for syndicated content belongs to the linked Source.
